



Effect of reactive oxygen species scavengers, antiinflammatory drugs, and calcium-channel blockers on carbon dioxide pneumoperitoneum-enhanced adhesions in a laparoscopic mouse model

M. M. Binda,¹ C. R. Molinas,² A. Bastidas,¹ P. R. Koninckx¹

¹ Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Herestraat 49 Bus 611, B3000 Leuven, Belgium

² Centre for Gynaecological Endoscopy (Cendogyn), Centro Médico La Costa, Asunción, Paraguay

Received: 7 November 2006/Accepted: 17 January 2007

Abstract

Background: Postoperative adhesions are a clinical problem. They can cause female infertility, intestinal obstruction, chronic pelvic pain, and difficulties at the time of reoperation. A variety of approaches described to prevent adhesions have shown variable and inconsistent results. Therefore, this study aimed to evaluate most known substances in a laparoscopic mouse model to obtain quantitative and comprehensive information on adhesion prevention. Specifically, this first study aimed to investigate the effects of reactive oxygen species (ROS) scavengers, antiinflammatory agents, and a calcium-channel blocker on pneumoperitoneum-enhanced adhesions.

Methods: Adhesions were induced during laparoscopy in BALB/c female mice by creation of a bipolar lesion. Carbon dioxide (CO₂) pneumoperitoneum was maintained for 60 min using humidified CO₂. Six experiments were conducted to evaluate the effects of ROS scavengers (superoxide dismutase [SOD], catalase, melatonin, and ascorbic acid), antiinflammatory agents (dexamethasone, tenoxicam, ibuprofen, parecoxib, nimesulide, anti-tumor necrosis factor [TNF]-alpha), and a calcium-channel blocker (diltiazem). Adhesions were scored after 7 days during laparotomy.

Results: Adhesions were reduced by SOD ($p < 0.01$, proc general linear methods (GLM) of experiments 1 and 2), diltiazem ($p = 0.05$, Wilcoxon), and dexamethasone ($p < 0.03$), but not by nonsteroidal antiinflammatory drugs (NSAIDs) nor by anti-TNF-alpha. When all the experiments were grouped for analysis, adhesions also decreased with one and three doses of SOD ($p <$

0.01 and $p < 0.01$, respectively) and with one and three doses of ascorbic acid ($p < 0.02$ and $p = 0.05$, respectively).

Conclusions: These experiments confirm that SOD, diltiazem, and dexamethasone can decrease adhesion formation. The absence of effect from the other antiinflammatory drugs and anti-TNF-alpha is surprising.

Key words: Antiinflammatory agents — Calcium-channel blockers — Laparoscopy — Pneumoperitoneum-enhanced adhesions — Prevention — ROS scavengers

Postoperative adhesion formation remains an important clinical problem because it causes intestinal obstruction [1], chronic pelvic pain [2], female infertility [3], and difficulties at the time of reoperation. However, adhesion prevention still is inadequate and poorly understood overall.

In animal models, adhesion prevention has been studied during both open and laparoscopic surgery. During open surgery, many products have been demonstrated to decrease postoperative adhesion formation, including corticosteroids, [4–7], nonsteroidal antiinflammatory drugs (NSAIDs) [6, 8–19], fibrinolytic agents [20], surfactants [21–25], flotation agents and semisolid barriers [23, 26–28], mechanical barriers [26, 29–32], hormones [33], calcium-channel blockers [34–38], reactive oxygen species (ROS) scavengers [39–45], and antiangiogenesis therapy [46, 47]. It should be stressed that these observations generally were reported with the use of only one drug in different models with different species and using different scoring systems. Therefore, a comprehensive quantitative evaluation of efficacy in one model still is lacking.




Fig. 1. Laparoscopic mouse model.

Prevention of adhesion formation after laparoscopic surgery has been poorly addressed. Some products have been demonstrated to decrease postoperative adhesions during laparoscopy including antibodies against vascular endothelial growth factor receptor 1 (VEGF-R1) [48], crystalloids [49, 50], 4% icodextrin [50], ferric hyaluronate gel [50–52], Sepracat [53], a crosslinked hyaluronan solution [54], and hyaluronate membrane [55].

Effectiveness after open surgery for humans was demonstrated in clinical trials for the SprayGel adhesion barrier system [56], Seprafilm [57], Intergel solution [58], 0.5% ferric hyaluronate [59, 60], Sepracat (HAL-C) solution [61], Interceed [62–64], and glycerol hyaluronate/carboxymethylcellulose [65]. In addition, the following products also were effective in preventing adhesions after laparoscopic surgery in clinical trials: SprayGel adhesion barrier system [56], Interceed [66], Viscoelastic gel [67] and Hyalobarrier Gel [68].

During laparoscopy, a pneumoperitoneum is necessary. This carbon dioxide (CO₂) pneumoperitoneum has been identified as a cofactor in adhesion formation. Mesothelial hypoxia is suggested as the driving mechanism because adhesion formation increased with insufflation pressure and with duration of pneumoperitoneum, because similar effects were observed with CO₂ and helium pneumoperitoneum, and because the addition of 2% to 4% of oxygen to both CO₂ and helium pneumoperitoneum decreased adhesion formation [69, 70]. This hypothesis also was supported by the observation that pneumoperitoneum-enhanced adhesion formation was absent in mice deficient in genes encoding for factors upregulated by hypoxia, such as hypoxia-inducible factors [71], vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) [72], and plasminogen activator 1 [73].

In addition, we demonstrated that both temperature and desiccation increased adhesion formation [74, 75].

These observations led to the conclusion that the mechanisms involved in adhesion formation after CO₂ pneumoperitoneum may be different from those observed after laparotomy. This also led to new concepts of adhesion prevention such as the addition of 3% oxygen to the pneumoperitoneum [76, 77], the use of anti-VEGF-R1 antibodies [48], using anti-PlGF antibodies [72], and lowering of body temperature [74]. In this model, we demonstrated that avoidance of desiccation prevented adhesion formation [75], whereas the addition of more than 3% oxygen to the pneumoperitoneum increased adhesions [77]. This led to the hypothesis that ROS could be another cofactor in adhesion formation [78].

Because ROS scavengers, antiinflammatory drugs, and calcium-channel blockers have not been investigated for the prevention of pneumoperitoneum-enhanced adhesions, this study aimed to evaluate these drugs in our laparoscopic mouse model. These experiments are part of a series intended to evaluate most known substances in one model to obtain quantitative and comprehensive information on adhesion prevention.

Materials and methods

The laparoscopic mouse model for adhesion formation

The experimental setup (i.e., animals, anesthesia and ventilation, laparoscopic surgery, and induction and scoring of intraperitoneal adhesions) has been described in detail previously [49, 71–77]. Briefly, the model consisted of pneumoperitoneum-enhanced adhesions induced during laparoscopy by creation of a mechanical lesion. The pneumoperitoneum was kept for 60 min using pure and humidified CO₂ at 15 mmHg of insufflation pressure. Gas and body temperatures were kept strictly at 37°C using a heated chamber (Fig. 1).

Animals

This study used 192 female 9- to 10-week-old BALB/c mice weighing 20 g. The animals were kept under standard laboratory conditions. They were fed using a standard laboratory diet with free access to food and water any time. The study was approved by the Institutional Review Animal Care Committee.

Anesthesia and ventilation

The mice were anesthetized with intraperitoneal pentobarbital 0.08 mg/g, intubated with a 20-gauge catheter, and mechanically ventilated (Mouse Ventilator MiniVent, Type 845; Hugo Sachs Elektronik-Harvard Apparatus GmbH, March-Hugstetten, Germany) using humidified room air with a tidal volume of 250 μ l at 160 strokes/min. Humidified air for ventilation was used to prevent cooling as occurs during ventilation with nonhumidified air [74].

Laparoscopic surgery

A midline incision was performed caudal to the xyphoides. A 2-mm endoscope with a 3.3-mm external sheath for insufflation (Karl Storz, Tuttlingen, Germany) was introduced into the abdominal cavity, and the incision was closed gas tight around the endoscope to avoid leakage.

Pneumoperitoneum was created with pure CO₂ at 15 mmHg insufflation pressure using the Thermoflator Plus (Karl Storz) and a water valve to damper pressure changes. The gas was humidified (Storz Humidifier 204320 33; Karl Storz), and the whole setup was kept in a 37°C chamber to obtain CO₂ at 37°C and with 100% relative humidity. As described previously, we maintained a controlled 23-ml/min flow of CO₂ through the abdominal cavity using a 26-gauge needle to ascertain a continuous 100% CO₂ environment by constant removal of any oxygen that might have diffused from the capillaries.

Induction of intraperitoneal adhesions

Pneumoperitoneum-enhanced adhesion formation was induced by maintaining the pneumoperitoneum for 60 min and creating standardized 10 \times 1.6-mm lesions in the antimesenteric border of both the right and left uterine horns and the pelvic sidewalls with bipolar coagulation (BICAP bipolar hemostasis probe, BP-5200A, 5 Fr, 200 cm; IMMED Benelux, Linkebeek, Belgium) at 20 W (Autocon 200; Karl Storz, standard coagulation mode).

Scoring of adhesions

Adhesions were qualitatively and quantitatively scored. Scoring was performed blindly, with the investigator not informed of the group being evaluated, after 7 days during laparotomy under microscopic vision. The qualitative scoring system assessed extent (0 [no adhesions], 1 [1–25% of the injured surface involved], 2 [26–50%], 3 [51–75%], 4 [76–100%]), type (0 [no adhesions], 1 [filmy], 2 [dense], 3 [capillaries present]), tenacity (0 [no adhesions], 1 [easily falls apart], 2 [requires traction], 3 [requires sharp dissection]), and total (extent + type + tenacity).

The quantitative scoring system assessed the proportion of the lesions covered by adhesions using the following formula: adhesion (%) = (sum of the lengths of the individual attachments/length of the lesion) \times 100. The results are presented as the average of the adhesions formed at the four individual sites (right and left visceral and parietal peritoneum), which were individually scored.

Products

ROS scavengers

Superoxide dismutase from bovine erythrocytes and catalase from murine liver (Sigma, Bornem, Belgium) were dissolved in saline (NaCl

0.9%) to 3,000 U/ml and kept at –20°C and 4°C until used, respectively. Melatonin (Sigma) was dissolved in ethanol (60 mg/ml) and kept protected from the light at –20°C. The day of the experiment, it was diluted in saline to 2 mg/ml immediately before use. Ascorbic acid (AA) (Sigma) was dissolved to 20 mg/ml in saline before use.

Antiinflammatory drugs

Dexamethasone (Acidexam 5 mg for injection; Organon, Bruxelles, Belgium) was prepared the day of the experiment as indicated in the product data sheet, diluted to 80 μ g/ml in phosphate-buffered saline (PBS), and kept at 4°C. Nimesulide (Sigma) was dissolved in dimethyl sulphoxide (30 mg/ml), kept at –20°C, and diluted to 0.2 mg/ml in PBS the day of the experiment. Parecoxib (Dynastat injectable; Pfizer, Bruxelles, Belgium) was prepared the day of the experiment as indicated in the product data sheet, diluted to 0.2 mg/ml in PBS, and kept at 4°C. Ibuprofen 10 mg/ml (Office Chimique-Certa S.P.R.L., Braine l'alleud, Belgium) was diluted to 2.8 mg/ml in PBS and kept at 4°C until used. Intravenous (IV) tenoxicam (Tilcotil; Roche, Bruxelles, Belgium) was prepared the day of the experiment as indicated in the product data sheet, diluted to 0.4 mg/ml in PBS, and kept at 4°C.

Anti-TNF-alpha antibody

A neutralizing antibody against mouse tumor necrosis factor (TNF)-alpha and a nonneutralizing antibody (used as a control condition) were kindly provided by Centocor B.V., Leiden, The Netherlands. The concentration of both antibodies was 10 mg/ml. Neutralizing antibodies were diluted to 1 mg/ml and to 0.1 mg/ml in saline and kept at –20°C.

Calcium-channel blockers

Diltiazem hydrochloridum (Tildiem 25 mg IV; Sanofi-Synthelabo S.A.N.V., Bruxelles, Belgium) was prepared the day of the experiment as indicated in the product data sheet, diluted to 0.2 mg/ml in saline, and kept at 4°C.

All the drugs were diluted in saline except the drugs of the experiment, which were diluted with nimesulide. In this experiment, the dilutions were made in PBS because nimesulide precipitated in saline (pH of 5.5) and was completely dissolved in PBS (pH of 7.4).

At least minimally effective doses, according to the literature, were chosen. For superoxide dismutase (SOD) and catalase, 15,000 U/kg, administered intraperitoneally (IP) was chosen because this dose given intravenously (IV) was shown to be effective in rats [39]. For melatonin, 10 mg/kg IP was used because it was shown to be effective in rats [42]. For AA, 100 mg/kg IP was used because it was shown to be effective in guinea pigs [79]. In addition, AA 80 and 250 mg/kg IP also were effective in mice [80, 81]. For the diet supplement, AA 8% was used because this concentration was shown to increase the dehydroascobate plasma concentration [82]. For dexamethasone, 2 mg/kg IP was used because 1 mg/kg was effective in rabbits [6]. For nimesulide, 5 mg/kg IP was used because 2.5 mg/kg was effective in rats [9]. For parecoxib, the same dose as with nimesulide was used because they both are a selective NSAID. For Ibuprofen, 70 mg/kg IP was used because this dose was shown to be effective in rabbits [14]. For tenoxicam, 10 mg/kg IP was used because 5 mg/kg IP was shown to be effective in mice [10]. For anti-TNF-alpha, 0.01, 0.1, and 1 mg IP were used because 1 mg IP was shown to be effective in mice [83]. For diltiazem, two daily doses 5 mg/kg IP were used because one daily dose of 10 mg/kg IP was shown to be effective in rats [38]. This drug was strictly controlled because overdoses can produce hypotension and bradycardia [84].

Experimental design

The time of anesthesia injection was considered time 0 (T₀). The animal preparation and ventilation started after exactly 10 min (T₁₀). The pneumoperitoneum was started at 20 min (T₂₀) and maintained for 60 min, until T₈₀. For all the experiments, eight animals per group were used.

Table 1. Prevention of pneumoperitoneum-enhanced adhesions in a laparoscopic mouse model^a

Experiment	Group	No. of doses	Route of administration	Dose	Quantitative scoring (Proportion, %)	Qualitative scoring (Total)
1	Control (saline)	1	IP	—	27.8 ± 2.8	3.5 ± 0.4
	SOD	1	IP	300 U	17.5 ± 4.2 ^{b,c}	2.6 ± 0.5 ^c
	Catalase	1	IP	300 U	31.3 ± 5.0	3.7 ± 0.5
	Melatonin	1	IP	200 µg	27.2 ± 2.5	3.6 ± 0.3
	AA	1	IP	2 mg	22.1 ± 3.2 ^c	3.5 ± 0.4
2	Control (saline)	3	IP	—	30.6 ± 3.1	3.4 ± 0.3
	SOD	3	IP	300 U	21.8 ± 3.1 ^{b,c}	3.1 ± 0.1 ^c
	AA	3	IP	2 mg	23.1 ± 4.6 ^c	3.3 ± 0.5
	SOD + AA	3	IP	300 U; 2 mg	27.2 ± 3.8	3.5 ± 0.3
	Control (PBS)	2	IP	—	34.6 ± 2.0	5.0 ± 0.3
3	Control (PBS)	4	IP	—	33.7 ± 4.1	4.2 ± 0.4
	Dexamethasone	2	IP	40 µg	23.4 ± 2.3 ^{c,d}	3.2 ± 0.1 ^{c,d}
	Nimesulide	4	IP	100 µg	26.8 ± 3.7	3.8 ± 0.2
	Parecoxib	4	IP	100 µg	34.1 ± 4.4	4.1 ± 0.4
	Ibuprofen	4	IP	1.4 mg	28.8 ± 2.2	4.0 ± 0.4
	Tenoxicam	2	IP	200 µg	36.4 ± 2.8	3.9 ± 0.7
	Control (Ab)	1	IP	1 mg	29.9 ± 3.8	3.3 ± 0.3
	Anti-TNFα Ab, 0.01	1	IP	0.01 mg	23.0 ± 7.6	3.2 ± 0.6
	Anti-TNFα Ab, 0.1	1	IP	0.1 mg	34.6 ± 6.6	3.4 ± 0.5
	Anti-TNFα Ab, 1	1	IP	1 mg	37.1 ± 5.4	3.6 ± 0.4
5	Control (Ab)	1	IV	1 mg	26.9 ± 3.4	3.6 ± 0.8
	Anti-TNFα Ab, 1	1	IV	1 mg	28.1 ± 2.8	2.5 ± 0.8
6	Control (saline)	4	IP	—	35.7 ± 3.4	3.9 ± 0.3
	Diltiazem	4	IP	100 µg	22.5 ± 4.6 ^{c,d}	3.0 ± 0.5 ^c

IP, intraperitoneal; SOD, superoxide dismutase; AA, ascorbic acid; PBS, phosphate-buffered saline; TNF, tumor necrosis factor; IV, intravenous; Ab, antibody

^a Carbon dioxide (CO₂) pneumoperitoneum using humidified gas at 15 mmHg was maintained for 60 min. Adhesions were induced during laparoscopy by performing a bipolar lesion. Six experiments were performed evaluating the effects of reactive oxygen species (ROS) scavengers (SOD, catalase, melatonin and ascorbic acid), antiinflammatories (dexamethasone, tenoxicam, ibuprofen, parecoxib, nimesulide and anti-TNF-alpha antibodies) and a calcium channel blocker (diltiazem). In this table, quantitative (proportion) and qualitative (total) scores are presented (mean ± standard error of the mean). The volumes administrated per dose were 100 µl for experiments 1, 4, and 5; 200 µl for experiment 2; and 500 µl for experiments 3 and 6

^b $p < 0.05$: Experiments 1 and 2 analyzed together (proc general linear methods [GLM], 2 groups, 2 variables [i.e., experiment and treatment])

^c $p < 0.05$: Interexperiment comparisons (each group compared with a control group grouping all the control subjects) (Wilcoxon test)

^d $p < 0.05$: Intraexperiment comparisons (each group compared with its own control group) (Wilcoxon test)

To make the table clearer, only the comparisons to the control groups were placed

Experiment 1 (5 groups) was designed to evaluate the effect of ROS scavengers on adhesion formation. Because it is well known that ROS scavengers are produced during reperfusion, 100 µl of SOD, catalase, melatonin, and AA were injected IP at T₇₅ (i.e., 5 min before the pneumoperitoneum was ended). Similarly, 100 µl of saline was injected in the control group.

Because some inhibitory effect was shown with SOD and AA, experiment 2 (4 groups) was designed for a more detailed study on the effect from higher doses of SOD, AA, and the combination of both on adhesion formation. In this experiment, 100 µl of SOD + 100 µl of saline (SOD group), 100 µl of AA + 100 µl of saline (AA group), 100 µl of SOD + 100 µl of AA (SOD + AA group), or 200 µl of saline (control group) were administrated IP at the beginning (T₂₀), before completion (T₇₅), and 30 min after completion of the pneumoperitoneum (T₁₁₀). In addition, the mice of groups AA and SOD + AA received AA orally (PO) in their food (Harlan Special Diet 2018 containing 8% ascorbic acid; Horst, The Nederland) 1 week before and after the surgery.

Experiment 3 (7 groups) was designed to evaluate the effect of steroidal (dexamethasone) and cyclooxygenase-2 (COX-2) nonselective (ibuprofen and tenoxicam) and COX-2 selective (nimesulide, parecoxib) NSAIDs on adhesion formation. For the dexamethasone and tenoxicam groups, the mice received two IP doses of 500 µl (immediately after creation of the lesion and on the day after the surgery) because these drugs have a very long half-life (36–72 h and 67 h, respectively) [85, 86]. The mice in the nimesulide, parecoxib, and ibuprofen groups received four IP doses of 500 µl (immediately after creation of the lesion, 6 h later, the day after the surgery in the morning, and 6 h later) because those drugs have a shorter half-life (1.80–4.73 h, 7 h, and 2–4 h, respectively) [85, 87, 88]. Two control groups were used, receiving two and four saline doses of 500 µl, respectively, in the same way as the treated groups.

Experiment 4 (4 groups) was designed to evaluate the effect of anti-TNF-alpha antibodies administered IP on adhesion formation. Immediately after induction of the pneumoperitoneum, 100 µl of either nonneutralizing antibodies 1 mg (control group) or anti-TNF-alpha antibodies 0.01 mg, 0.1 mg, or 1 mg were injected IP under laparoscopic vision.

Experiment 5 (2 groups) was designed to evaluate the effect of anti-TNF-alpha antibodies administered IV on adhesion formation. The day before the surgery, either nonneutralizing antibodies 1 mg/100 µl (control group) or anti-TNF-alpha antibodies 1 mg/100 µl were injected IV in the vein of the animal tail.

Experiment 6 (2 groups) was designed to evaluate the effect of a calcium-channel blocker, diltiazem, on adhesion formation. Because diltiazem has a short half-life (1.5–7 h) [89], the mice received four IP doses of 500 µl (immediately after creation of the lesion, 6 h later, on the day after the surgery in the morning, and 6 h later). Similarly, four saline doses of 500 µl were administered in the control group.

Statistical analysis

Statistical analyses were performed using the SAS System (SAS Institute, Cary, NC, USA). Differences in adhesion formation were evaluated with the Wilcoxon test and with procedure general linear methods (proc GLM) for a two-way analysis of variance (ANOVA) of the data from experiments 1 and 2. In Table 1, all the data are presented as the mean ± standard error of the mean. To represent all data in one figure, proportion data (mean ± standard deviation) were divided by the mean of the their control group and multiplied by 100 to be expressed as a percentage of the control subjects.




Fig. 2. Prevention of pneumoperitoneum-enhanced adhesions in a laparoscopic mouse model. Carbon dioxide pneumoperitoneum (humidified gas at 15 mmHg) was maintained for 60 min. Adhesions were induced during laparoscopy by performing a bipolar lesion. Six experiments were performed evaluating the effects of reactive oxygen species (ROS) scavengers (superoxide dismutase, catalase, melatonin, and ascorbic acid), antiinflammatories (dexamethasone, tenoxicam, ibuprofen, parecoxib, nimesulide, and anti-tumor necrosis factor [TNF]-alpha antibodies), and a calcium-channel blocker (diltiazem). Proportions of adhesions are indicated. For visualization of the re-

sults for all the experiments in one graph, the percentage of change in comparison with the controls is given for each treatment. The coefficient of variation for all the controls is indicated as the shadowed area. ^a $p < 0.05$: Intraexperiment comparisons (each group compared with its own control group) (Wilcoxon test). ^b $p < 0.05$: Experiments 1 and 2 analyzed together (proc general linear methods [GLM], 2 groups, 2 variables [i.e., experiment and treatment]); p value of the variable treatment. ^c $p < 0.05$: Interexperiment comparisons (each group compared with a control group grouping all the controls) (Wilcoxon test).

Results

The results of all six experiments are presented in Table 1. In experiments 1 and 2, the effect of the ROS scavengers, catalase, SOD, melatonin, and AA were evaluated. When both experiments were analyzed together (proc GLM, 2 groups, 2 variables [i.e., experiment and treatment]), SOD reduced adhesion formation: effect of treatment (proportion: $p < 0.01$; extent: $p < 0.01$); effect of experiment (not significant). None of the other drugs showed any important effect on adhesion formation, neither when the two experiments were analyzed together nor when they were analyzed as single experiments (Wilcoxon).

In experiment 3, the effect of antiinflammatory drugs was evaluated. First, no differences were found between two and four doses of saline injected IP in the control groups (Wilcoxon). Dexamethasone reduced adhesion formation (proportion: $p < 0.03$, total: $p = 0.01$; extent: $p < 0.02$, type: $p < 0.01$, tenacity: $p < 0.01$), but no significant effect was observed when ibuprofen, tenoxicam, nimesulide, and parecoxib were used. The mice treated with dexamethasone had less adhesions than the mice treated with tenoxicam (proportion: $p = 0.02$, total: $p < 0.04$, extent: $p < 0.04$), but not less adhesions than the mice treated with nimesulide, parecoxib, and ibuprofen.

In experiments 4 and 5, the effect of neutralizing anti-TNF-alpha antibodies was analyzed. In comparison with the control group, the IP administration of 0.01, 0.1, and 1 mg and the IV administration of 1 mg of the neutralizing antibodies did not have any effect on

adhesion formation. In experiment 6, the effect of a calcium-channel blocker was analyzed. Diltiazem reduced adhesion formation in comparison with the control group (proportion: $p = 0.05$).

The results of all the experiments can be visualized in Fig. 2. Adhesion formation in the control groups during the six experiments was comparable (proc GLM, 2 variables [i.e., experiment and block, nonsignificant effect for both]), with a coefficient of variation of 10% only. Given this low variability of adhesion formation between the experiments, a reanalysis was performed grouping the control groups in all the experiments (total, 56) as the comparator. As expected, this confirmed the effects of SOD, dexamethasone, and diltiazem. In addition, adhesions decreased with one IP dose of SOD (proportion: $p < 0.01$, total: $p < 0.01$, extent: $p < 0.01$, type: $p < 0.01$) and with three IP doses of SOD (proportion: $p < 0.01$, total: $p < 0.01$, extent: $p < 0.01$). Moreover, adhesions decreased with one IP dose of AA (proportion: $p < 0.02$, extent: $p < 0.02$) and with the combined use of three IP ascorbic acid doses together with PO administration (proportion: $p = 0.05$).

Discussion

In open surgery models for adhesion formation effectiveness of ROS scavengers, antiinflammatory drugs, and calcium-channel blockers have been shown, albeit in isolated experiments with mice [10, 45], rats [4, 5, 7–9, 11–13, 16, 38–40, 42–44], hamsters [36], and rabbits [6, 14, 15, 17, 18, 31, 34, 37, 41]. In our pneumoperitoneum-

enhanced adhesion mouse model, ROS scavengers (only SOD was significant), dexamethasone and a calcium-channel blocker (diltiazem) decreased adhesion formation, whereas no effect was found for NSAIDs, even for specific COX-2 inhibitors or for anti-TNF-alpha antibodies. These data should be interpreted cautiously because results from one species do not necessarily apply to other species.

In open surgery, ROS scavengers have been described as reducing adhesion formation in mice [45], rats [39, 40, 42–44], and rabbits [41], but the effect is not consistent (e.g., vitamin E failed to decrease adhesion formation in rats) [90]. In our laparoscopic mouse model, we confirmed that ROS scavengers can decrease adhesion formation, although the overall effect was small. It is not surprising that not all products decreased adhesions significantly given the small number of animals in each group. Increasing the number of animals and repeating the experiments would not have changed the message that ROS scavengers can be effective but the effect is small. It is unlikely but cannot be excluded that IP administration such as we used is less effective than IV administration. Possibly, results differ between mice and rats. In rats the same dose of SOD and catalase (i.e., 15,000 U/kg IV) decreased intraperitoneal adhesions [39]. Also for melatonin, the same IP dose of 10 mg/kg body weight was effective in rats [42].

Most important, however, is that effectiveness is more pronounced after open surgery because exposure to air with approximately 21% of oxygen (i.e., a partial pressure of 160 mmHg) may generate much more ROS than the ischemia–reperfusion process after laparoscopy. In conclusion, we confirmed in our laparoscopic mouse model that ROS scavengers can reduce adhesion formation but the effect is small.

Antiinflammatory drugs are widely accepted for reducing adhesion formation in mice [10, 91], rats [4, 5, 7–9, 11–13, 16], and rabbits [6, 14, 15, 17–19]. However, these effects have not always been consistent in open surgery models. Ibuprofen failed to reduce adhesion formation in rats [7]. Anti-TNF-alpha antibodies also failed to reduce adhesions in a rat cecal serosal abrasion model [92]. In our laparoscopic mouse model, we confirmed the effectiveness of dexamethasone, but failed to demonstrate any important effects of NSAIDs as COX-1 and COX-2 inhibitors or of neutralizing anti-TNF-alpha antibodies.

Taken together, these data after both open surgery and laparoscopy suggest that this inflammatory reaction may be less important for adhesion formation. The absence of effect from anti-TNF-alpha antibodies with their strong effects on inflammation supports this suggestion. The fact that dexamethasone, nevertheless, had some effect on adhesion prevention suggests the involvement of other mechanisms. Glucocorticoids indeed can inhibit fibroblast proliferation and can have immunosuppressive effects on the production and release of cytokines [85].

Diltiazem, a calcium-channel blocker, reduced adhesion formation in our laparoscopic model, confirming the results for open surgery [34–38]. The suggested cause of this effect involves mechanisms such as

interference with the inflammatory response [93], protection against the toxic effect of the ischemic–reperfusion cell injury [94], and activation of cellular processes [95].

The current understanding of adhesion formation comprises several mechanisms including the initial inflammatory reaction, with exudation and fibrin deposition, and fibroblast migration or differentiation, as well as a role for macrophages and later angiogenesis and collagen deposition. These experiments question the importance of the inflammatory reaction while confirming the effectiveness of ROS scavengers (SOD and AA) and calcium-channel blockers (diltiazem), at least in our model.

These obviously are screening experiments. It remains to be confirmed that the conclusion is valid for other species, especially primates, and for other adhesion formation models. Unfortunately the cost and effort associated with experiments of sufficient size with larger animals is prohibitive for screening experiments. Our screening data nevertheless warrant evaluating at least ROS scavengers such as SOD and AA, antiinflammatory drugs such as dexamethasone, and calcium-channel blockers such as diltiazem.

In conclusion, we confirmed with our laparoscopic mouse model the effects of ROS scavengers, calcium-channel blockers, and dexamethasone. The absence of effect from the other antiinflammatory drugs and anti-TNF-alpha antibodies is surprising. It is clear that we currently can begin to identify mechanisms and players, but we are far from a comprehensive understanding of the adhesion formation process and its prevention.

Acknowledgments. We thank R. Pijnenborg, PhD, Ms. R. Van Bree, J. Verguts, MD, L. Ret, MD, C. De Cicco, MD, and L. Vercruyse, MSc (Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg) for their help. This study was supported by Onderzoeks Toelagen Katholieke Universiteit Leuven (Leuven, Belgium grant TBA/00/27) and in part by Karl Storz Endoscopy (Tuttlingen, Germany).

References

1. Ellis H (1997) The clinical significance of adhesions: focus on intestinal obstruction. *Eur J Surg Suppl* 577: 5–9
2. Duffy DM, diZerega GS (1996) Adhesion controversies: pelvic pain as a cause of adhesions, crystalloids in preventing them. *J Reprod Med* 41: 19–26
3. Drake TS, Grunert GM (1980) The unsuspected pelvic factor in the infertility investigation. *Fertil Steril* 34: 27–31
4. Zhang YD, Yao W, Wu CX, Chi QM, Zhang JY, Li M (2002) Tropical application of halcinonide cream reduces the severity and incidence of intraperitoneal adhesions in a rat model. *Am J Surg* 184: 74–77
5. Cohen BM, Heyman T, Mast D (1983) Use of intraperitoneal solutions for preventing pelvic adhesions in the rat. *J Reprod Med* 28: 649–653
6. Siegler AM, Kontopoulos V, Wang CF (1980) Prevention of postoperative adhesions in rabbits with ibuprofen, a nonsteroidal anti-inflammatory agent. *Fertil Steril* 34: 46–49
7. Luciano AA, Hauser KS, Benda J (1983) Evaluation of commonly used adjuvants in the prevention of postoperative adhesions. *Am J Obstet Gynecol* 46: 88–92
8. Aldemir M, Ozturk H, Erten C, Buyukbayram H (2004) The preventive effect of Rofecoxib in postoperative intraperitoneal adhesions. *Acta Chir Belg* 104: 97–100

9. Guvenal T, Cetin A, Ozdemir H, Yanar O, Kaya T (2001) Prevention of postoperative adhesion formation in rat uterine horn model by nimesulide: a selective COX-2 inhibitor. *Hum Reprod* 16: 1732–1735
10. Celebioglu B, Eslambouli NR, Olcay E, Atakan S (1999) The effect of tenoxicam on intraperitoneal adhesions and prostaglandin E2 levels in mice. *Anesth Analg* 88: 939–942
11. Golan A, Bernstein T, Wexler S, Neuman M, Bukovsky I, David MP (1991) The effect of prostaglandins and aspirin—an inhibitor of prostaglandin synthesis—on adhesion formation in rats. *Hum Reprod* 6: 251–254
12. DeSimone JM, Meguid MM, Kurzer M, Westervelt J (1988) Indomethacin decreases carrageenan-induced peritoneal adhesions. *Surgery* 104: 788–795
13. Tayyar M, Basbug M (1999) The effects of intraperitoneal piroxicam and low-molecular-weight heparin in prevention of adhesion reformation in rat uterine horn. *Res Exp Med (Berlin)* 198: 269–275
14. Nishimura K, Nakamura RM, diZerega GS (1983) Biochemical evaluation of postsurgical wound repair: prevention of intraperitoneal adhesion formation with ibuprofen. *J Surg Res* 34: 219–226
15. Nishimura K, Nakamura RM, diZerega GS (1984) Ibuprofen inhibition of postsurgical adhesion formation: a time and dose response biochemical evaluation in rabbits. *J Surg Res* 36: 115–124
16. De Leon FD, Odom J, Hudkins P, Vijayakumar R, Heine MW (1986) Orally and parenterally administered ibuprofen for postoperative adhesion prevention. *J Reprod Med* 31: 1014–1016
17. Wiseman DM, Huang WJ, Johns DB, Rodgers KE, diZerega GS (1994) Time-dependent effect of tolmetin sodium in a rabbit uterine adhesion model. *J Invest Surg* 7: 527–532
18. Rodgers K, Girgis W, diZerega GS, Bracken K, Richer L (1990) Inhibition of postsurgical adhesions by liposomes containing nonsteroidal antiinflammatory drugs. *Int J Fertil* 35: 315–320
19. Rodgers K, Girgis W, diZerega GS, Johns DB (1990) Intraperitoneal tolmetin prevents postsurgical adhesion formation in rabbits. *Int J Fertil* 35: 40–45
20. Hellebrekers BW, Trimbos-Kemper TC, Trimbos JB, Emeis JJ, Kooistra T (2000) Use of fibrinolytic agents in the prevention of postoperative adhesion formation. *Fertil Steril* 74: 203–212
21. Muller SA, Treutner KH, Tietze L, Jansen M, Anurov M, Titkova S, Oettinger AP, Schumpelick V (2002) Influence of early drainage of intraperitoneal phospholipids on efficacy of adhesion prevention. *J Invest Surg* 15: 23–28
22. Muller SA, Treutner KH, Jorn H, Anurov M, Oettinger AP, Schumpelick V (2002) Phospholipids reduce adhesion formation in the rabbit uterine horn model. *Fertil Steril* 77: 1269–1273
23. Muller SA, Treutner KH, Anurov M, Titkova S, Oettinger AP, Schumpelick V (2003) Experimental evaluation of phospholipids and icodextrin in re-formation of peritoneal adhesions. *Br J Surg* 90: 1604–1607
24. Ar'Rajab A, Ahren B, Rozga J, Bengmark S (1991) Phosphatidylcholine prevents postoperative peritoneal adhesions: an experimental study in the rat. *J Surg Res* 50: 212–215
25. Ar'Rajab A, Snoj M, Larsson K, Bengmark S (1995) Exogenous phospholipid reduces postoperative peritoneal adhesions in rats. *Eur J Surg* 161: 341–344
26. Ustun C, Kocak I, Akpolat I (2000) Effects of Seprafilm (sodium hyaluronate-based bioresorbable), Sepracoat (0.4% hyaluronic acid), and Ringer's lactate on the prevention of postsurgical adhesion formation in rat models. *J Obstet Gynaecol* 20: 78–80
27. Harris ES, Morgan RF, Rodeheaver GT (1995) Analysis of the kinetics of peritoneal adhesion formation in the rat and evaluation of potential antiadhesive agents. *Surgery* 117: 663–669
28. Reijnen MM, Skrabut EM, Postma VA, Burns JW, van Goor H (2001) Polyanionic polysaccharides reduce intraabdominal adhesion and abscess formation in a rat peritonitis model. *J Surg Res* 101: 248–253
29. Hellebrekers BW, Trimbos-Kemper GC, van Blitterswijk CA, Bakkum EA, Trimbos JB (2000) Effects of five different barrier materials on postsurgical adhesion formation in the rat. *Hum Reprod* 15: 1358–1363
30. Eroglu A, Demirci S, Kurtman C, Akbay A, Eroglu N (2001) Prevention of intraabdominal adhesions by using Seprafilm in rats undergoing bowel resection and radiation therapy. *Colorectal Dis* 3: 33–37
31. Dunn R, Lyman MD, Edelman PG, Campbell PK (2001) Evaluation of the SprayGel adhesion barrier in the rat cecum abrasion and rabbit uterine horn adhesion models. *Fertil Steril* 75: 411–416
32. Leach RE, Henry RL (1990) Reduction of postoperative adhesions in the rat uterine horn model with poloxamer 407. *Am J Obstet Gynecol* 162: 1317–1319
33. Canbaz MA, Ustun C, Kocak I, Yanik FF (1999) The comparison of gonadotropin-releasing hormone agonist therapy and intraperitoneal Ringer's lactate solution in prevention of postoperative adhesion formation in rat models. *Eur J Obstet Gynecol Reprod Biol* 82: 219–222
34. Steinleitner A, Lambert H, Kazensky C, Sanchez I, Sueldo C (1990) Reduction of primary postoperative adhesion formation under calcium-channel blockade in the rabbit. *J Surg Res* 48: 42–45
35. Dunn RC, Steinleitner AJ, Lambert H (1991) Synergistic effect of intraperitoneally administered calcium-channel blockade and recombinant tissue plasminogen activator to prevent adhesion formation in an animal model. *Am J Obstet Gynecol* 164: 1327–1330
36. Steinleitner A, Lambert H, Montoro L, Kelly E, Swanson J, Sueldo C (1988) The use of calcium-channel blockade for the prevention of postoperative adhesion formation. *Fertil Steril* 50: 818–821
37. Steinleitner A, Kazensky C, Lambert H (1989) Calcium-channel blockade prevents postsurgical reformation of adnexal adhesions in rabbits. *Obstet Gynecol* 74: 796–798
38. Golan A, Wexler S, Lotan G, Abramov L, Langer R, David MP (1989) Calcium antagonist: effect on adhesion formation. *Acta Obstet Gynecol Scand* 68: 529–532
39. Tsimoyiannis EC, Tsimoyiannis JC, Sarros CJ, Akalestos GC, Moutesidou KJ, Lekkas ET, Kotoulas OB (1989) The role of oxygen-derived free radicals in peritoneal adhesion formation induced by ileal ischaemia/reperfusion. *Acta Chir Scand* 155: 171–174
40. Tsimoyiannis EC, Lekkas ET, Paizis JB, Boulis SA, Page P, Kotoulas OB (1990) Prevention of peritoneal adhesions in rats with trimetazidine. *Acta Chir Scand* 156: 771–774
41. Portz DM, Elkins TE, White R, Warren J, Adadevoh S, Randolph J (1991) Oxygen free radicals and pelvic adhesion formation: I. Blocking oxygen free radical toxicity to prevent adhesion formation in an endometriosis model. *Int J Fertil* 36: 39–42
42. Ozelik B, Serin IS, Basbug M, Uludag S, Narin F, Tayyar M (2003) Effect of melatonin in the prevention of postoperative adhesion formation in a rat uterine horn adhesion model. *Hum Reprod* 18: 1703–1706
43. Hemadeh O, Chilukuri S, Bonet V, Hussein S, Chaudry IH (1993) Prevention of peritoneal adhesions by administration of sodium carboxymethyl cellulose and oral vitamin E. *Surgery* 114: 907–910
44. de la Portilla F, Ynfante I, Bejarano D, Conde J, Fernandez A, Ortega JM, Carranza G (2004) Prevention of peritoneal adhesions by intraperitoneal administration of vitamin E: an experimental study in rats. *Dis Colon Rectum* 47: 2157–2161
45. Kagoma P, Burger SN, Seifter E, Levenson SM, Demetriou AA (1985) The effect of vitamin E on experimentally induced peritoneal adhesions in mice. *Arch Surg* 120: 949–951
46. Chiang SC, Cheng CH, Moulton KS, Kasznica JM, Moulton SL (2000) TNP-470 inhibits intraabdominal adhesion formation. *J Pediatr Surg* 35: 189–196
47. Saltzman AK, Olson TA, Mohanraj D, Carson LF, Ramakrishnan S (1996) Prevention of postoperative adhesions by an antibody to vascular permeability factor/vascular endothelial growth factor in a murine model. *Am J Obstet Gynecol* 174: 1502–1506
48. Molinas CR, Binda MM, Carmeliet P, Koninckx PR (2004) Role of vascular endothelial growth factor receptor 1 in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in mice. *Fertil Steril* 82(Suppl 3): 1149–1153
49. Elkemani OA, Molinas CR, Mynbaev O, Koninckx PR (2002) Prevention of adhesions with crystalloids during laparoscopic surgery in mice. *J Am Assoc Gynecol Laparosc* 9: 447–452
50. Roman H, Canis M, Kamble M, Botchorishvili R, Pouly JL, Mage G (2005) Efficacy of three adhesion-preventing agents in reducing severe peritoneal trauma induced by bipolar coagulation in a laparoscopic rat model. *Fertil Steril* 83(Suppl 1): 1113–1118

51. Detchev R, Bazot M, Soriano D, Darai E (2004) Prevention of de novo adhesion by ferric hyaluronate gel after laparoscopic surgery in an animal model. *JSL S* 8: 263–268
52. De Iaco PA, Stefanetti M, Pressato D, Piana S, Dona M, Pavesio A, Bovicelli L (1998) A novel hyaluronan-based gel in laparoscopic adhesion prevention: preclinical evaluation in an animal model. *Fertil Steril* 69: 318–323
53. Ozmen MM, Aslar AK, Terzi MC, Albayrak L, Berberoglu M (2002) Prevention of adhesions by bioresorbable tissue barrier following laparoscopic intraabdominal mesh insertion. *Surg Laparosc Endosc Percutan Tech* 12: 342–346
54. De Iaco P, Costa A, Mazzoleni G, Pasquinelli G, Bassein L, Marabini A (1994) Fibrin sealant in laparoscopic adhesion prevention in the rabbit uterine horn model. *Fertil Steril* 62: 400–404
55. Kramer K, Senninger N, Herbst H, Probst W (2002) Effective prevention of adhesions with hyaluronate. *Arch Surg* 137: 278–282
56. Mettler L (2003) Pelvic adhesions: laparoscopic approach. *Ann N Y Acad Sci* 997: 255–268
57. Vrijland WW, Tseng LN, Eijkman HJ, Hop WC, Jakimowicz JJ, Leguit P, Stassen LP, Swank DJ, Haverlag R, Bonjer HJ, Jeekel H (2002) Fewer intraperitoneal adhesions with use of hyaluronic acid-carboxymethylcellulose membrane: a randomized clinical trial. *Ann Surg* 235: 193–199
58. Johns DB, Keyport GM, Hoehler F, diZerega GS (2001) Reduction of postsurgical adhesions with Intergel adhesion prevention solution: a multicenter study of safety and efficacy after conservative gynecologic surgery. *Fertil Steril* 76: 595–604
59. Thornton MH, Johns DB, Campeau JD, Hoehler F, diZerega GS (1998) Clinical evaluation of 0.5% ferric hyaluronate adhesion prevention gel for the reduction of adhesions following peritoneal cavity surgery: open-label pilot study. *Hum Reprod* 13: 1480–1485
60. Lunderoff P, van Geldorp H, Tronstad SE, Lalos O, Larsson B, Johns DB, diZerega GS (2001) Reduction of postsurgical adhesions with ferric hyaluronate gel: a European study. *Hum Reprod* 16: 1982–1988
61. Diamond MP (1998) Reduction of de novo postsurgical adhesions by intraoperative precoating with Sepracoat (HAL-C) solution: a prospective, randomized, blinded, placebo-controlled multicenter study. The Sepracoat Adhesion Study Group. *Fertil Steril* 69: 1067–1074
62. Interceed (TC7) Adhesion Barrier Study Group (1989) Prevention of postsurgical adhesions by Interceed (TC7), an absorbable adhesion barrier: a prospective randomized multicenter clinical study. *Fertil Steril* 51: 933–938
63. Franklin RR (1995) Reduction of ovarian adhesions by the use of Interceed. Ovarian Adhesion Study Group. *Obstet Gynecol* 86: 335–340
64. Sekiba K (1992) Use of Interceed (TC7) absorbable adhesion barrier to reduce postoperative adhesion reformation in infertility and endometriosis surgery. The Obstetrics and Gynecology Adhesion Prevention Committee. *Obstet Gynecol* 79: 518–522
65. Cohen Z, Senagore AJ, Dayton MT, Koruda MJ, Beck DE, Wolff BG, Fleshner PR, Thirlby RC, Ludwig KA, Larach SW, Weiss EG, Bauer JJ, Holmdahl L (2005) Prevention of postoperative abdominal adhesions by a novel, glycerol/sodium hyaluronate/carboxymethylcellulose-based bioresorbable membrane: a prospective, randomized, evaluator-blinded multicenter study. *Dis Colon Rectum* 48: 1130–1139
66. Keckstein J, Ulrich U, Sasse V, Roth A, Tuttlies F, Karageorgieva E (1996) Reduction of postoperative adhesion formation after laparoscopic ovarian cystectomy. *Hum Reprod* 11: 579–582
67. Lunderoff P, Donnez J, Korell M, Audebert AJ, Block K, diZerega GS (2005) Clinical evaluation of a viscoelastic gel for reduction of adhesions following gynaecological surgery by laparoscopy in Europe. *Hum Reprod* 20: 514–520
68. Pellicano M, Bramante S, Cirillo D, Palomba S, Bifulco G, Zullo F, Nappi C (2003) Effectiveness of autocrosslinked hyaluronic acid gel after laparoscopic myomectomy in infertile patients: a prospective, randomized, controlled study. *Fertil Steril* 80: 441–444
69. Molinas CR, Koninckx PR (2000) Hypoxaemia induced by CO₂ or helium pneumoperitoneum is a cofactor in adhesion formation in rabbits. *Hum Reprod* 15: 1758–1763
70. Mynbaev OA, Molinas CR, Adamyan LV, Vanacker B, Koninckx PR (2002) Reduction of CO₂-pneumoperitoneum-induced metabolic hypoxaemia by the addition of small amounts of O₂ to the CO₂ in a rabbit ventilated model: a preliminary study. *Hum Reprod* 17: 1623–1629
71. Molinas CR, Campo R, Elkelani OA, Binda MM, Carmeliet P, Koninckx PR (2003) Role of hypoxia-inducible factors 1alpha and 2alpha in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice. *Fertil Steril* 80(Suppl 2): 795–802
72. Molinas CR, Campo R, Dewerchin M, Eriksson U, Carmeliet P, Koninckx PR (2003) Role of vascular endothelial growth factor and placental growth factor in basal adhesion formation and in carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice. *Fertil Steril* 80(Suppl 2): 803–811
73. Molinas CR, Elkelani O, Campo R, Luttun A, Carmeliet P, Koninckx PR (2003) Role of the plasminogen system in basal adhesion formation and carbon dioxide pneumoperitoneum-enhanced adhesion formation after laparoscopic surgery in transgenic mice. *Fertil Steril* 80: 184–192
74. Binda MM, Molinas CR, Mailova K, Koninckx PR (2004) Effect of temperature upon adhesion formation in a laparoscopic mouse model. *Hum Reprod* 19: 2626–2632
75. Binda MM, Molinas CR, Hansen P, Koninckx PR (2006) Effect of desiccation and temperature during laparoscopy on adhesion formation in mice. *Fertil Steril* 86: 166–175
76. Molinas CR, Mynbaev O, Pauwels A, Novak P, Koninckx PR (2001) Peritoneal mesothelial hypoxia during pneumoperitoneum is a cofactor in adhesion formation in a laparoscopic mouse model. *Fertil Steril* 76: 560–567
77. Elkelani OA, Binda MM, Molinas CR, Koninckx PR (2004) Effect of adding more than 3% oxygen to carbon dioxide pneumoperitoneum on adhesion formation in a laparoscopic mouse model. *Fertil Steril* 82: 1616–1622
78. Binda MM, Molinas CR, Koninckx PR (2003) Reactive oxygen species and adhesion formation: clinical implications in adhesion prevention. *Hum Reprod* 18: 2503–2507
79. Kukner AS, Kukner A, Naziroglu M, Colakoglu N, Celebi S, Yilmaz T, Aydemir O (2004) Protective effects of intraperitoneal vitamin C, aprotinin, and melatonin administration on retinal edema during experimental uveitis in the guinea pig. *Cell Biochem Funct* 22: 299–305
80. Jagetia GC, Rajanikant GK, Baliga MS, Rao KV, Kumar P (2004) Augmentation of wound healing by ascorbic acid treatment in mice exposed to gamma-radiation. *Int J Radiat Biol* 80: 347–354
81. Tantecheva LP, Stoeva ES, Galabov AS, Braykova AA, Savov VM, Mileva MM (2003) Effect of vitamin E and vitamin C combination on experimental influenza virus infection. *Methods Find Exp Clin Pharmacol* 25: 259–264
82. Tsao CS, Leung PY, Young M (1987) Effect of dietary ascorbic acid intake on tissue vitamin C in mice. *J Nutr* 117: 291–297
83. Han X, Benight N, Osuntokun B, Loesch K, Frank S, Denson L (2007) Tumour necrosis factor {alpha} blockade induces an anti-inflammatory growth hormone–signaling pathway in experimental colitis. *Gut* 56(1): 73–81
84. DeWitt CR, Waksman JC (2004) Pharmacology, pathophysiology, and management of calcium-channel blocker and beta-blocker toxicity. *Toxicol Rev* 23: 223–238
85. Burke A, Smyth E, FitzGerald GA (2006) Analgesic-antipyretic agents: pharmacotherapy of gout. In: Brunton LL, Lazo JS, Parker KL (eds). *Goodman and Gilman's the pharmacological basis of therapeutics*. McGraw-Hill, New York, NY, USA, pp 671–715; 1593–1610
86. Nilsen OG (1994) Clinical pharmacokinetics of tenoxicam. *Clin Pharmacokinet* 26: 16–43
87. Bernareggi A (1998) Clinical pharmacokinetics of nimesulide. *Clin Pharmacokinet* 35: 247–274
88. Yuan JJ, Yang DC, Zhang JY, Bible R Jr, Karim A, Findlay JW (2002) Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human. *Drug Metab Dispos* 30: 1013–1021
89. Eisenberg MJ, Brox A, Bestawros AN (2004) Calcium-channel blockers: an update. *Am J Med* 116: 35–43
90. Sanfilippo JS, Booth RJ, Burns CD (1995) Effect of vitamin E on adhesion formation. *J Reprod Med* 40: 278–282

91. Greene AK, Alwayn IP, Nose V, Flynn E, Sampson D, Zurakowski D, Folkman J, Puder M (2005) Prevention of intraabdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. *Ann Surg* 242: 140–146
92. Kaidi AA, Nazzal M, Gurchumelidze T, Ali MA, Dawe EJ, Silva YJ (1995) Preoperative administration of antibodies against tumor necrosis factor-alpha (TNF-alpha) and interleukin-1 (IL-1) and their impact on peritoneal adhesion formation. *Am Surg* 61: 569–572
93. Szabo C, Hasko G, Nemeth ZH, Vizi ES (1997) Calcium entry blockers increase interleukin-10 production in endotoxemia. *Shock* 7: 304–307
94. Wang QD, Pernow J, Sjoquist PO, Ryden L (2002) Pharmacological possibilities for protection against myocardial reperfusion injury. *Cardiovasc Res* 55: 25–37
95. Elmslie KS (2004) Calcium-channel blockers in the treatment of disease. *J Neurosci Res* 75: 733–741